



## AROA BIOSURGERY FULL YEAR RESULTS WEBINAR

---

Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX) is pleased to announce it will hold a webinar with CEO Brian Ward and CFO James Agnew on Tuesday 24 May 2022 at 11.30am AEST to discuss the Full Year 2022 Financial Results which will be released pre-market the same day.

Investors and interested parties can register for the webinar via the following link:

[https://us02web.zoom.us/webinar/register/WN\\_ukIJypWTpzdHbSzL90EHg](https://us02web.zoom.us/webinar/register/WN_ukIJypWTpzdHbSzL90EHg)

Investors are invited to submit questions prior to the webinar to [shinsley@aroabio.com](mailto:shinsley@aroabio.com) or do so via the Q&A function on Zoom.

< ENDS >

**Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.**

### **Contacts**

#### *Investor*

Simon Hinsley  
Investor Relations  
[shinsley@aroabio.com](mailto:shinsley@aroabio.com)  
+ 61 401 809 653

#### *Media*

Australia  
Matthew Wright  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)  
+61 451 896 420

New Zealand  
Piet De Jong  
[piet.dejong@baldwinboyle.com](mailto:piet.dejong@baldwinboyle.com)  
+64 21 812 766

### **About AROA™**

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. AROA's products have been used in more than four and a half million procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX:ARX). [www.aroabio.com/](http://www.aroabio.com/)

### **About Myriad™**

Myriad Matrix™ is an extracellular matrix graft, composed of AROA ECM and designed for soft tissue reconstruction and complex wounds. Myriad Morcells™ is a powder format of Myriad Matrix that easily conforms to optimize contact with irregular wound beds.



**About Endoform™**

Endoform™ products are unique extracellular matrix products, composed of AROA ECM, for the management of acute and chronic wounds.

**About Symphony™**

Symphony is a new product which has been developed off the strength of AROA ECM. It is applied as a graft and is surgically fixed at the margins. It is designed to support healing during the proliferative phase to reduce time to wound closure, particularly in patients whose healing is severely impaired or compromised due to disease.

**About AROA's dead space management platform technology**

This is a new system which AROA is developing, designed to close tissue cavities at a surgical site created by surgical dissection or tissue removal. It is comprised of a specially designed AROA ECM implant that is coupled to an external single-use negative pressure pump. When the product is deployed, the tissue surfaces are drawn together, held in place and tissue fluids are carried by the vacuum to an external fluid collection bag. AROA intends to develop and launch a new class of products utilising this new platform technology.